Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On ArgenxBenzinga • 03/22/22
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular DisorderBenzinga • 03/22/22
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia GravisBusiness Wire • 03/22/22
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/03/22
argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 03/03/22
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022GlobeNewsWire • 02/24/22
argenx to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/10/22
12 biotech stocks to consider buying now as prospects for the sector brighten this yearMarket Watch • 02/06/22
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia GravisBusiness Wire • 01/20/22
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia GravisBusiness Wire • 12/17/21
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/28/21
argenx Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 10/28/21
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021GlobeNewsWire • 10/21/21